Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel.
KRAS
PDAC
TP53
mutations
next-generation sequencing
pancreatic cancer
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
23 Apr 2022
23 Apr 2022
Historique:
received:
29
03
2022
revised:
16
04
2022
accepted:
18
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Despite the efforts made in the management of PDAC, the 5-year relative survival rate of pancreatic ductal adenocarcinoma (PDAC) still remains very low (10%). To date, precision oncology is far from being ready to be applied in cases of PDAC, although studies exploring the molecular and genetic alterations have been conducted, and the genomic landscape of PDAC has been characterized. This study aimed to apply a next-generation sequencing (NGS) laboratory-developed multigene panel to PDAC samples to find molecular alterations that could be associated with histopathological features and clinical outcomes. A total of 68 PDACs were characterized by using a laboratory-developed multigene NGS panel.
Identifiants
pubmed: 35626213
pii: diagnostics12051058
doi: 10.3390/diagnostics12051058
pmc: PMC9139796
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer. 2020 Sep 1;126(17):3939-3949
pubmed: 32573775
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
Gut. 2021 Jan;70(1):148-156
pubmed: 32350089
Gastroenterology. 2013 Nov;145(5):1098-1109.e1
pubmed: 23912084
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Ann Surg Oncol. 2009 Dec;16(12):3316-22
pubmed: 19707831
World J Gastroenterol. 2021 Jun 7;27(21):2710-2726
pubmed: 34135550
Pancreatology. 2020 Jun;20(4):778-780
pubmed: 32205062
Diagnostics (Basel). 2020 Apr 23;10(4):
pubmed: 32340363
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Nature. 2012 Nov 15;491(7424):399-405
pubmed: 23103869
Cell. 2021 Sep 16;184(19):5031-5052.e26
pubmed: 34534465
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
J Pathol. 2018 Dec;246(4):395-404
pubmed: 30105857
Cancers (Basel). 2020 May 24;12(5):
pubmed: 32456277
World J Surg Oncol. 2014 Nov 27;12:360
pubmed: 25429841
Gut Liver. 2014 Jan;8(1):102-8
pubmed: 24516708
Endosc Ultrasound. 2019 Jul-Aug;8(4):261-268
pubmed: 31115386
Mod Pathol. 2003 Sep;16(9):902-12
pubmed: 13679454
Pancreas. 2006 Apr;32(3):271-5
pubmed: 16628082
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Ann Oncol. 2019 Aug 1;30(8):1395-1397
pubmed: 31168599
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Medicine (Baltimore). 2016 Apr;95(17):e3452
pubmed: 27124039
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
Cancer Biomark. 2018 Feb 6;21(2):323-334
pubmed: 29103024
Clin Cancer Res. 2019 Apr 1;25(7):2194-2205
pubmed: 30385653
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Eur Surg Res. 2018;59(5-6):329-338
pubmed: 30453288
J Exp Clin Cancer Res. 2020 Oct 28;39(1):227
pubmed: 33115526
Surgery. 2020 Dec;168(6):1003-1014
pubmed: 32321665
Ann Surg. 2013 Aug;258(2):336-46
pubmed: 23470568
J Hematol Oncol. 2020 Oct 2;13(1):130
pubmed: 33008426
Gastroenterology. 2021 Sep;161(3):899-909.e5
pubmed: 34116031
Pancreas. 2017 Mar;46(3):335-340
pubmed: 28099251
J Clin Oncol. 2017 Oct 10;35(29):3330-3337
pubmed: 28817370
J Gastrointest Surg. 2008 Apr;12(4):701-6
pubmed: 18027062
Pancreas. 2008 Nov;37(4):352-7
pubmed: 18665012
Surgery. 2012 Sep;152(3 Suppl 1):S43-9
pubmed: 22763261